BioArctic AB
STO:BIOA B

Watchlist Manager
BioArctic AB Logo
BioArctic AB
STO:BIOA B
Watchlist
Price: 202 SEK -5.08% Market Closed
Market Cap: 17.8B SEK
Have any thoughts about
BioArctic AB?
Write Note

Relative Value

The Relative Value of one BIOA B stock under the Base Case scenario is 131.54 SEK. Compared to the current market price of 202 SEK, BioArctic AB is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIOA B Relative Value
Base Case
131.54 SEK
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
44
vs Industry
18
Median 3Y
85
Median 5Y
88.7
Industry
7.6
Forward
62.9
vs History
vs Industry
2
Median 3Y
-55.7
Median 5Y
-81.8
Industry
22.1
Forward
-100.4
vs History
vs Industry
3
Median 3Y
-69.7
Median 5Y
-81
Industry
21.9
vs History
vs Industry
2
Median 3Y
-66.5
Median 5Y
-74.5
Industry
23.4
vs History
31
vs Industry
4
Median 3Y
18.5
Median 5Y
13.8
Industry
2.5
vs History
41
vs Industry
14
Median 3Y
83
Median 5Y
84.6
Industry
7.5
Forward
60.9
vs History
30
vs Industry
9
Median 3Y
46.3
Median 5Y
77.1
Industry
9.3
vs History
vs Industry
2
Median 3Y
-37
Median 5Y
-58.8
Industry
4.2
Forward
-67.3
vs History
vs Industry
1
Median 3Y
-47.9
Median 5Y
-65.2
Industry
4
Forward
-72.7
vs History
vs Industry
2
Median 3Y
-63.7
Median 5Y
-74.2
Industry
5.9
vs History
vs Industry
3
Median 3Y
-61.8
Median 5Y
-70.7
Industry
3.9
vs History
87
vs Industry
9
Median 3Y
173.3
Median 5Y
152.2
Industry
4.5

Multiples Across Competitors

BIOA B Competitors Multiples
BioArctic AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
BioArctic AB
STO:BIOA B
17.9B SEK 106.8 -76.7 -68.3 -68.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
314.9B USD 5.7 62.1 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
140.6B USD 4.3 33.4 16 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 4.1 920.7 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD 9.9 -218.6 21.3 22.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.3 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD 5.6 16.8 15.2 16.9
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.3 -109.3 -79.6
P/S Multiple
Revenue Growth P/S to Growth
SE
BioArctic AB
STO:BIOA B
Average P/S: 3 467 709.8
106.8
161%
0.7
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.3
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
SE
BioArctic AB
STO:BIOA B
Average P/E: 213
Negative Multiple: -76.7
192%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
920.7
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -218.6
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
BioArctic AB
STO:BIOA B
Average EV/EBITDA: 16.3
Negative Multiple: -68.3
288%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.2
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
BioArctic AB
STO:BIOA B
Average EV/EBIT: 21.4
Negative Multiple: -68.3
247%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.2
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

See Also

Discover More
Back to Top